TLDR Docetaxel is safe and works well for older people with cancer, with manageable side effects.
Docetaxel was found to be safe and effective for elderly patients with various solid tumor malignancies, with Phase II studies indicating no significant differences in efficacy or toxicity due to age. The drug's side effects, including myelosuppression and fatigue, were the most common, but others such as alopecia, skin toxicity, and fluid retention were also noted. These side effects tended to be dose-related and manageable through dose adjustments or therapy delays. Weekly dosing schedules of docetaxel were found to be as effective as every 3-week schedules and may reduce the risk of myelosuppression, a concern in the elderly population. Overall, docetaxel was commonly used in treating elderly cancer patients.
January 2021 in “Annals of translational medicine” YH0618 helped reduce skin and nail problems and fatigue in chemotherapy patients.
18 citations,
January 2017 in “Postępy Dermatologii i Alergologii” EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
15 citations,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
38 citations,
February 2012 in “Supportive Care in Cancer” Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
19 citations,
October 2008 in “Journal der Deutschen Dermatologischen Gesellschaft” Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
5 citations,
April 2014 in “Journal of Lipid Research” SCD1 inhibitors can cause skin issues in rodents.
